Aura Biosciences, Inc. (AURA) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
AURA currently has 60.3M outstanding shares. with limited dilution risk as only 5.15M additional shares (8.5%) are authorized for issuance. The company has diluted shareholders by 20.93% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Mar 30, 2026 |
10-K filing | 60.3M shares outstanding |
60M | 5.2M |
| Aug 13, 2025 |
10-Q filing | 58.0M shares outstanding |
58M | 5.2M |
| May 15, 2025 |
10-Q filing | 50.1M shares outstanding |
50M | 5.2M |
| Mar 24, 2025 |
10-K filing | 49.7M shares outstanding |
50M | 5.2M |
| Nov 12, 2024 |
10-Q filing | 49.7M shares outstanding |
50M | 5.2M |
| Aug 08, 2024 |
10-Q filing | 49.5M shares outstanding |
50M | 5.2M |
| May 09, 2024 |
10-Q filing | 49.5M shares outstanding |
49M | 5.2M |
| Mar 27, 2024 |
S-3 filing: Aura Biosciences files an S-3 form to register the offering of common stock, preferred stock, and debt securities, with a total proposed amount of $350,000,000. They also filed a prospectus supplement, dated March 27, 2024, for offering of common stock up to $75,000,000 through Jefferies LLC as a sales agent. |
38M | 5.2M |
| Mar 27, 2024 |
10-K filing | 49.5M shares outstanding |
50M | 5.2M |
| Nov 09, 2023 |
8-K filing: Aura Biosciences, Inc. completed an offering of 11,000,000 shares of common stock at a price of $9.00 per share, resulting in net proceeds of approximately $92.6 million for the company. ($99.0M proceeds) |
38M | 5.2M |
| Nov 09, 2023 |
10-Q filing | 38.2M shares outstanding |
38M | 5.2M |
| Aug 09, 2023 |
10-Q filing | 37.9M shares outstanding |
38M | 5.2M |
| May 11, 2023 |
10-Q filing | 37.8M shares outstanding |
38M | 5.2M |
| Mar 15, 2023 |
10-K filing | 37.8M shares outstanding |
38M | 5.2M |
| Nov 10, 2022 |
10-Q filing | 29.3M shares outstanding |
29M | 5.2M |
| Nov 01, 2022 |
S-3 filing: Aura Biosciences files an S-3 form to register a shelf offering of up to $250,000,000 in common stock, preferred stock, debt securities, warrants, and/or units and an additional offering for common stock up to $75,000,000 through Jefferies LLC as sales agent. |
29M | 5.2M |
| Aug 11, 2022 |
10-Q filing | 29.3M shares outstanding |
29M | 5.2M |
| May 12, 2022 |
10-Q filing | 29.3M shares outstanding |
29M | 5.2M |
| Mar 23, 2022 |
10-K filing | 29.2M shares outstanding |
29M | 5.2M |
| Nov 24, 2021 |
10-Q filing | 29.2M shares outstanding |
29M | 5.2M |
| Oct 25, 2021 |
S-1/A filing: This S-1/A filing relates to an offering of common stock with an over-allotment option. The company intends to use the net proceeds from this offering to advance the clinical development of AU-011 for the treatment of choroidal melanoma and NMIBC, to develop our platform and for general corporate purposes. |
23M | 5.2M |